Cat. No.: HY-B0497G

Niclosamide (GMP)

(Synonyms: BAY2353 (GMP))

Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research. Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells.

For research use only. We do not sell to patients.

CAS No.: 50-65-7
Formula: C₁₃H₈Cl₂N₂O₄
Molecular Weight:327.12

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

Niclosamide (GMP) Chemical Structure

CAS No.: 50-65-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research^[1]. Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells^[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells^[2]^[3]^[5].

All Antibiotic Isoforms :

All STAT Isoforms :

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	8.8 μM Compound: 5	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24900231]
A549	CC₅₀	22.9 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay	[PMID: 33112138]
A549	CC₅₀	22.9 μM Compound: 6	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 32045239]
A549	IC₅₀	0.4 μM Compound: Niclosamide	Antiproliferative activity against human A549 cells after 120 hrs by MTT assay Antiproliferative activity against human A549 cells after 120 hrs by MTT assay	[PMID: 16680159]
A549	IC₅₀	3 μM Compound: 5	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900231]
ASPC1	IC₅₀	1.47 μM Compound: 1	Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
ASPC1	IC₅₀	1.47 μM Compound: Niclosamide	CYtotoxicity against human AsPC1 cells by MTS assay CYtotoxicity against human AsPC1 cells by MTS assay	[PMID: 23416191]
BHK-21	CC₅₀	>20 μM Compound: 104	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Bone marrow cell	IC₅₀	>10 μM Compound: 89	Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 μM Compound: 1	Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
CWR22R	IC₅₀	1.61 μM Compound: 1	Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
DLD-1	IC₅₀	2.39 μM Compound: Niclosamide	Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
DU-145	IC₅₀	0.7 μM Compound: 5	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24900231]
DU-145	IC₅₀	0.7 μM Compound: 5	Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis	[PMID: 24900231]
DU-145	IC₅₀	3.65 μM Compound: 1	Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
HCT-116	EC₅₀	0.056 μM Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
HCT-116	IC₅₀	0.25 μM Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
HCT-116	IC₅₀	0.32 μM Compound: 53	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method	[PMID: 38142509]
HCT-116	IC₅₀	0.41 μM Compound: Niclosamide	Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HCT-116	IC₅₀	0.45 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 26272032]
HCT-116	IC₅₀	0.45 μM Compound: Niclosamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
HEK293	IC₅₀	0.34 μM Compound: 1	Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs	[PMID: 26272032]
HEK293	IC₅₀	0.34 μM Compound: 1	Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay	[PMID: 30551901]
HEK293	IC₅₀	0.4 μM Compound: Niclosamide	Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay	[PMID: 23453073]
HEK293	IC₅₀	1.53 μM Compound: 89	Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz	[PMID: 31253529]
HeLa	IC₅₀	0.25 μM Compound: 5	Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay	[PMID: 24900231]
HeLa	IC₅₀	1.4 μM Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900231]
HepG2 2.2.15	CC₅₀	>100 μM Compound: Niclosamide	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
HL-60	IC₅₀	0.3 μM Compound: 89	Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
HT-29	IC₅₀	0.13 μM Compound: Niclosamide	Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HT-29	IC₅₀	4.66 μM Compound: 53	Antiproliferative activity against human HT-29 cells measured after 72 hrs by SRB method Antiproliferative activity against human HT-29 cells measured after 72 hrs by SRB method	[PMID: 38142509]
HT-29	IC₅₀	7.2 μM Compound: 5	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 24900231]
J774.A1	CC₅₀	42.11 μM Compound: 33	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
Jurkat	IC₅₀	0.4 μM Compound: 89	Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
KG-1	IC₅₀	0.36 μM Compound: 89	Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
LN-229	IC₅₀	0.3 μM Compound: 77	Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
LNCaP	IC₅₀	0.8 μM Compound: 1	Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
LoVo	IC₅₀	0.7 μM Compound: Niclosamide	Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay	[PMID: 16680159]
MCF7	IC₅₀	1.06 μM Compound: 1	Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay	[PMID: 23459613]
MCF7	IC₅₀	1.06 μM Compound: Niclosamide	CYtotoxicity against ER-positive human MCF7 cells by MTS assay CYtotoxicity against ER-positive human MCF7 cells by MTS assay	[PMID: 23416191]
MCF7	IC₅₀	8.13 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MDA-MB-231	IC₅₀	0.625 μM Compound: 27	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.79 μM Compound: 1	Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 23459613]
MDA-MB-231	IC₅₀	0.79 μM Compound: Niclosamide	CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay	[PMID: 23416191]
MDA-MB-231	IC₅₀	0.8 μM Compound: Niclosamide	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
MDA-MB-231	IC₅₀	1.78 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MIA PaCa-2	IC₅₀	1.1 μM Compound: Niclosamide	Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay	[PMID: 16680159]
NALM-6	IC₅₀	0.62 μM Compound: 89	Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
PANC-1	IC₅₀	1.73 μM Compound: 1	Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
PANC-1	IC₅₀	1.73 μM Compound: Niclosamide	CYtotoxicity against human PANC1 cells by MTS assay CYtotoxicity against human PANC1 cells by MTS assay	[PMID: 23416191]
PC-3	IC₅₀	0.4 μM Compound: Niclosamide	Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay	[PMID: 16680159]
PC-3	IC₅₀	1.92 μM Compound: 1	Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
PC-3	IC₅₀	11.7 μM Compound: 5	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900231]
SH-SY5Y	IC₅₀	0.87 μM Compound: Niclosamide	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SK-N-AS	IC₅₀	2.33 μM Compound: Niclosamide	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SNB-19	IC₅₀	0.12 μM Compound: 1	Antiviral activity against Zika virus infected in SNB-19 cells assessed as reduction in viral titer Antiviral activity against Zika virus infected in SNB-19 cells assessed as reduction in viral titer	[PMID: 33689873]
SW480	IC₅₀	0.98 μM Compound: Niclosamide	Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
SW480	IC₅₀	1 μM Compound: 93	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay	[PMID: 33445154]
SW948	IC₅₀	0.11 μM Compound: Niclosamide	Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
T98G	IC₅₀	0.3 μM Compound: 77	Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U138-MG	IC₅₀	0.3 μM Compound: 77	Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U2OS	CC₅₀	>20 μM Compound: 104	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
U-373MG ATCC	IC₅₀	0.3 μM Compound: 77	Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.3 μM Compound: 77	Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.4 μM Compound: Niclosamide	Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay	[PMID: 16680159]
Vero	CC₅₀	>50 μM Compound: Niclosamide	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	CC₅₀	22.1 μM Compound: 21	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	CC₅₀	3.058 μM Compound: 33	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
Vero	EC₅₀	<0.1 μM Compound: 21	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	0.28 μM Compound: Niclosamide	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
Vero C1008	CC₅₀	>35.53 μM Compound: Niclosamide	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	CC₅₀	1.03 μM Compound: 1	Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35344901]
Vero C1008	CC₅₀	1.96 μM Compound: NIC	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	[PMID: 37058956]
Vero C1008	CC₅₀	100 μM Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay	[PMID: 35344901]
Vero C1008	EC₅₀	4.63 μM Compound: NIC	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay	[PMID: 37058956]

In Vitro

Niclosamide (0.6 nM-46 μM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells^[3].
Niclosamide (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells ^[4].
Niclosamide (10 μM) inhibits virus replication in Vero E6 cells.

Niclosamide (GMP) (up to 2 μM, 24 h) inhibites Zika virus infection in SNB-19 cells^[6].
Niclosamide (GMP) (1.5 μM，5 d) inhibites nuclear factor‐κB ligand (RANKL)-induced transdifferentiation of macrophages into osteoclast precursors, particularly in the early stage of osteoclastogenesis^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Niclosamide (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 50-65-7
Molecular Weight 327.12
Formula C₁₃H₈Cl₂N₂O₄
SMILES

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
Synonyms

BAY2353 (GMP)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [Content Brief]

[2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [Content Brief]

[3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [Content Brief]

[4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [Content Brief]

[5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. [Content Brief]

[6]. Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22(10):1101-1107. [Content Brief]

[7]. Jiao Y, Chen C, Hu X, et al. Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. FEBS Open Bio. 2020;10(8):1685-1697. doi:10.1002/2211-5463.12921 [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Niclosamide (GMP)

All Antibiotic Isoforms

All STAT Isoforms

All Parasite Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Niclosamide (GMP) Related Classifications

HY-B0497G Related Classifications